TRVITrevi Therapeutics, Inc.
$13.20+62% 1Y
$13.20
$8.3852 weeks$19.08
TRVI in its own filings
TRVI's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
143
Events found in the filings · across 536 filings · the record starts in 2018
- Hard flags
- 1
Hard flags
- Most recent filing
- Aug 6, 2026
Most recent filing · Form 10-Q
- Record starts
- Dec 18, 2018
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 12, 2026
- Delisting notice / listing-rule failurehistorical
- 2022-01-14
- SEC comment-letter activity19 occurrences
- 2023-08-14
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 6, 2026Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates.Earnings release · press release
- Jun 4, 2026At the Annual Meeting, the Company’s stockholders approved an amendment (the “Amendment”) to the Company’s restated certificate of incorporation (“Certificate of Incorporation”) to increase the number of authorized shares of the Company’s common stock from 200,000,0000 shares to 400,000,000 shares.Charter/bylaw amendment or fiscal-year change · Form 8-K
- May 5, 2026Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates.Earnings release · press release
- Apr 17, 2026On April 16, 2026, Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC and Leerink Partners LLC, as representatives of the several underwriters (the “Underwriters”), relating to an underwritten offering …Material agreement entered · Form 8-K
- Mar 17, 2026Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates.Earnings release · press release
- Mar 9, 2026On March 9, 2026, Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), announced results of the Company’s End-of-Phase 2 meeting with the U.S. Food and Drug Administration (the “FDA”)Other event · Form 8-K
- Dec 5, 2025On December 4, 2025, Trevi Therapeutics, Inc. (the “Company”) announced the hiring of David Hastings to serve as the Company’s Chief Financial Officer and principal financial officer, effective January 6, 2026.Director or officer change · Form 8-K
- Nov 13, 2025Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…